Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-11-29FDA Approved: FEBUXOSTAT — Supplemental Application (Tris Pharma Inc)
The FDA approved a supplemental application for febuxostat from Tris Pharma Inc, enabling a generic version of the gout medication.
-
FDA approval · 2023-11-28FDA Approved: FEBUXOSTAT — Supplemental Application (Solco Healthcare US LLC)
FDA approved a supplemental application for febuxostat from Solco Healthcare US LLC, authorizing changes to the approved product.
-
FDA approval · 2023-11-20FDA Approved: PROBENECID — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Probenecid filed by Rising Pharma Holdings, Inc., typically related to changes in labeling o…
-
FDA approval · 2023-11-20FDA Approved: PROBENECID — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings' original application for a generic probenecid product. Probenecid is a uricosuric agent used to tre…
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout [Phase 4]
Pilot Phase 4 trial evaluating etanercept for acute gout has been terminated; results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-25FDA Approved: FEBUXOSTAT — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for febuxostat submitted by Aurobindo Pharma Limited, authorizing marketing of a generic febuxostat pr…
-
FDA approval · 2023-10-24FDA Approved: PROBENECID AND COLCHICINE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved a generic fixed-dose combination tablet of probenecid and colchicine under ANDA217030 from Rising Pharma Holdings, Inc. for the…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy [Phase 2]
Phase 2 trial comparing SEL-212 to KRYSTEXXA in patients with chronic gout refractory to conventional therapy has been completed with result…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy [Phase 4]
Phase 4 study evaluating co-administration of pegloticase with methotrexate in patients with uncontrolled gout who previously failed pegloti…
-
CLINICAL_TRIALS research · 2023-10-04Clinical Trial Update: Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial [NA]
A completed behavioral trial study examining medication adherence patterns in rheumatic diseases and gout with results posted in 2023.
-
FDA approval · 2023-09-28FDA Approved: FEBUXOSTAT — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original Abbreviated New Drug Application (ANDA) for febuxostat tablets 40 mg and 80 mg by Macleods Pharmaceuticals Limited.…
-
FDA approval · 2023-09-19FDA Approved: FEBUXOSTAT — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for febuxostat filed by Zydus Lifesciences Limited under the ANDA.
-
FDA approval · 2023-09-18FDA Approved: ALLOPURINOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for allopurinol submitted by Mylan Pharmaceuticals Inc. (ANDA 018659).
-
FDA approval · 2023-08-15FDA Approved: FEBUXOSTAT — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for febuxostat from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2023-08-15FDA Approved: FEBUXOSTAT — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for febuxostat submitted by Ascend Laboratories, LLC.
-
FDA approval · 2023-08-09FDA Approved: FEBUXOSTAT — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Febuxostat submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-08-09FDA Approved: FEBUXOSTAT — Supplemental Application (DR REDDY'S LABORATORIES LIMITED)
The FDA approved a supplemental application for febuxostat submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-08-03FDA Approved: ALLOPURINOL — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' allopurinol via Original Application (ANDA 217748), granting a generic version of the drug.
-
FDA approval · 2023-07-26FDA Approved: FEBUXOSTAT — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for febuxostat from Alembic Pharmaceuticals Limited. The action indicates regulatory approval for a …
-
FDA approval · 2023-07-26FDA Approved: FEBUXOSTAT — Supplemental Application (Hikma Pharmaceuticals USA Inc)
FDA approved a supplemental application for febuxostat by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) [Phase 2]
Phase 2 trial update of ALLN-346 (engineered urate oxidase) in hyperuricemic subjects has completed enrollment and status.
-
FDA approval · 2023-06-16FDA Approved: LODOCO — Original Application (AGEPHA Pharma USA, LLC)
FDA approved LODOCO (colchicine tablets 0.5 mg) under an original NDA from AGEPHA Pharma USA, LLC.
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients [Phase 2]
Phase 2b trial evaluating AR882 for gout shows completed status; provides data on efficacy and safety in gout patients.
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Rasburicase Treatment in Chronic Gouty Arthritis [Phase 4]
Phase 4 clinical trial update evaluating rasburicase treatment for chronic gout.
-
FDA approval · 2023-04-17FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ULORIC (febuxostat) submitted by Takeda Pharmaceuticals America, Inc. This action updates th…